European Metrology Research Programme Delivering Impact





Simulating the effectiveness of radiotherapy at the nanometre scale

When using radiotherapy to treat cancer it is vital that the radiation dose delivered is accurate. However, the dose must be adjusted to the relative biological effectiveness (RBE) of different radiations. Since accurately predicting RBE is difficult, clinical centres can use significantly different radiation doses for the same cancer. Track structure simulations enable a better prediction of RBE and, thus, more harmonised treatments.

Europe's National Measurement Institutes working together

The European Metrology Research Programme (EMRP) brings together National Measurement Institutes in 23 countries to address key measurement challenges at a European level. It supports collaborative research to ensure that measurement science meets the future needs of industry and wider society.

Challenge

One in two people will develop cancer in their lifetime. Radiotherapy, using external sources of radiation, is a common treatment approach. This includes photon sources, such as x-rays and γ -rays, and particles, such as electrons, protons, and carbon ions. Radiation doses must be carefully calculated – too high a level and healthy tissue can be affected, too low and the cancerous cells may survive.

When radiation beams hit a cell energy is deposited, mainly through the production of secondary electrons which interact with the molecules in the medium. These interactions form nanometre scale patterns or 'particle track' structures which correlate with DNA damage. Different radiation types have different particle track structures and damage the DNA to a different extent, resulting in different biological effectiveness. Chemical changes ensue, including the formation of free radicals which also attack the DNA. This damage activates cellular repair mechanisms and influences cell survival.

Patient treatment plans aim to minimise the risk of adverse effects but often consider only the average radiation dose at volumes of millimetre dimensions, orders of magnitude higher than the nanometre-scale diameter of the DNA – considered to be the primary radiation target.

For particle beams different approaches are applied to account for the enhanced biological effectiveness. As a result, different centres employing the same treatment on the same condition can use up to a 20% different radiation dose.

Solution

During the EMRP BioQuaRT project, the French Institute for Radiological Protection and Nuclear Safety (IRSN) developed a DNA damage simulation chain, based on Geant4-DNA, an extension of the Geant4 Monte Carlo toolkit for track structure calculations and biological damage simulation.

An essential ingredient of these calculations are the 'cross-sections' for the interaction of radiation with the molecules in the medium. Prior to the BioQuaRT project, only water cross-sections were used in the Geant4-DNA code. In the project, cross-sections for the interaction of radiation beams with DNA constituents were measured.

Results were implemented into a new Geant4-DNA design and validated using the nanometric scale Monte Carlo code Ptra. A new geometrical DNA mode was implemented to include both direct energy depositions on DNA and subsequent free radicals on DNA damage. The long computational time required for the chemical stage limited models to a 30 nm diameter chromatin fibre, thus scaling procedures were used to extrapolate to a cell nucleus.

To validate the results in terms of early DNA damage (double strand breaks and chromosomal aberrations) experimental data was obtained from radiobiological experiments on endothelium cells.

The improved Geant4 simulation chain was able model the physical and chemical changes of ionising beams down to the diameter of biological molecules inside cells.

Impact

At the end of the project in 2015, IRSN, as member of the Geant4-DNA collaboration, further developed the code. In 2017 this was extended to incorporate modelling of the physical, physicochemical, and chemical stages of early radiation damage at the scale of an entire human genome. This was publicly released to the Geant4 community. In 2021, a new method termed IRT-sync, developed in the frame of the Geant4-DNA collaboration, was added to allow a faster simulation of the chemical stage, later extended to include DNA repair models.

The model can now compare the risks of one beam type to another and its predictive capabilities can replace complex and costly experiments.

IRNS acknowledge the help of the EMRP project in developing the code, especially the access to knowledge and laboratories of project partners such as PTB, the National Metrology Institute of Germany, who precisely measured the cross-section data of DNA constituents and gave access to its microbeam facility for radiobiological experiments.

The code will be extended in the future, validating it against clinical proton or carbon ion therapy treatments and extending it to cover new therapy types such as flash therapy. The new code will help radiotherapy plans, which consider both physical dose and the predicted treatment outcome. This will enable results from different radiotherapy centres in Europe to be more easily compared, reduce the need for expensive radiobiological cell and animal experiments, and provide better treatment for patients.

Improving dosimetry in radiotherapy treatments

The BioQuaRT project developed new instrumentation and concepts to better define the biological response to ionising radiation. A silicon micro-telescope was constructed and used, along with a miniature tissue-equivalent proportional counter (miniTEPC), to measure microdosimetric spectra of a clinical carbon ion beam. The Ion Counter nanodosimeter was upgraded by integrating the silicon micro-telescope to develop a prototype device for multi-scale measurement of particle track structure properties. Three nanodosimeter devices were characterised and used to propose a new qualifier for radiation quality. A Monte Carlo track structure simulation code, Geant4-DNA, was extended to simulate how radiation interacts with DNA. In addition, 108 presentations were given at international conferences, 42 articles published, 16 training courses given, 4 workshops held, and 8 reports provided to international standards committees.

The multiscale approach developed, from the DNA to the cellular level, will allow a better understanding of the effects of different radiations during therapy.





The EMRP is jointly funded by the EMRP participating countries within $\ensuremath{\mathsf{EURAMET}}$ and the European Union

www.euramet.org/project-SIB06

Hans Rabus

PTB, Germany hans.rabus@ptb.de